Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study.

Lee J, Kim HS, Jung CH, Park JY, Lee WJ

Diabetes/metabolism research and reviews13 May 2021Cited by 3 (Europe PMC)

PMID33957706DOI10.1002/dmrr.3466PepBankPUB-33957706

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In patients with type II diabetes switched from insulin, dulaglutide use was linked to reduced HbA1c after 6 months.
In plain wordsIn patients switched from insulin, dulaglutide use was linked to lower HbA1c after 6 months compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 98
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
HbA1c change
−0.95%
6 months
Source sentences
Summary
After treatment with dulaglutide for 6 months, patients experienced changes in HbA1c of -0.95% (95% confidence interval [CI]: -1.30% to -0.59%, P < 0.001) and in body weight of -1.75 kg (95% CI: -2.42 to -1.08 kg, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety-eight patients with T2DM who were switched from insulin to dulaglutide therapy were retrospectively evaluated. Changes in HbA1c concentrations were assessed after 6 months of consistent treatment with dulaglutide.
Report a problemFND-3395770601
02HumanObservational studyEfficacy outcome
In patients with type II diabetes switched from insulin, dulaglutide use was linked to reduced weight after 6 months.
In plain wordsIn patients switched from insulin, dulaglutide use was linked to lower weight after 6 months compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 98
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change
−1.75 kg
6 months
Source sentences
Summary
After treatment with dulaglutide for 6 months, patients experienced changes in HbA1c of -0.95% (95% confidence interval [CI]: -1.30% to -0.59%, P < 0.001) and in body weight of -1.75 kg (95% CI: -2.42 to -1.08 kg, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety-eight patients with T2DM who were switched from insulin to dulaglutide therapy were retrospectively evaluated. Changes in HbA1c concentrations were assessed after 6 months of consistent treatment with dulaglutide.
Report a problemFND-3395770602
03HumanObservational studySafety outcome
In patients switched from insulin to dulaglutide, gastrointestinal symptoms were the most frequent adverse events.
In plain wordsIn patients switched from insulin to dulaglutide, digestive symptoms were the most frequent adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal symptoms
Study
n = 98
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most frequent adverse events were gastrointestinal symptoms.
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety-eight patients with T2DM who were switched from insulin to dulaglutide therapy were retrospectively evaluated. Changes in HbA1c concentrations were assessed after 6 months of consistent treatment with dulaglutide.
Report a problemFND-3395770604

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients switched to dulaglutide, higher baseline HbA1c was linked to greater HbA1c reduction in multiple regression analysis.
In plain wordsIn patients switched to dulaglutide, higher starting HbA1c was linked to a larger HbA1c reduction.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBaseline HbA1c and HbA1c response
Study
n = 98
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Multiple linear regression analysis showed that higher baseline HbA1c was significantly associated with a greater reduction in HbA1c.
1 context sentence(design, population, supporting numbers)
Summary · context
Ninety-eight patients with T2DM who were switched from insulin to dulaglutide therapy were retrospectively evaluated. Changes in HbA1c concentrations were assessed after 6 months of consistent treatment with dulaglutide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3395770603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.